title: [(Micro-)hematuria (in adults). Main symptoms: evidence of erythrocytes in urine sediment].
authors.affiliation: Medizinisch Poliklinik, Universitätsspital Zürich.
authors.forename: G
authors.initials: G
authors.lastname: Schulthess
authors.forename: U
authors.initials: U
authors.lastname: Kolyvanos Naumann
authors.forename: L
authors.initials: L
authors.lastname: Käser
authors.forename: W
authors.initials: W
authors.lastname: Vetter
mesh_terms: D000328:Adult; D000367:Age Factors; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D004630:Emergencies; D005921:Glomerulonephritis / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy / Q000652:urine; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy / Q000652:urine; D006417:Hematuria / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003520:Cyclophosphamide; D011241:Prednisone